A bean alpha-amylase inhibitor formulation (starch blocker) is ineffective in man.

A commercial alpha-amylase inhibitor with potent inhibitory activity in vitro was used in a randomized double-blind, cross-over clinical trial in six nonobese, healthy adult males. In these subjects, this inhibitor had no effect on the response of blood glucose, insulin, or breath hydrogen to a standardized starch meal. It is concluded that this formulation has no effect on starch digestion in humans.